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Abstract
Background: The Ser358Leu mutation in TMEM43, encoding an inner nuclear membrane protein, has been
implicated in arrhythmogenic right ventricular cardiomyopathy (ARVC). The pathogenetic mechanisms of this
mutation are poorly understood.
Methods: To determine the frequency of TMEM43 mutations as a cause of ARVC, we screened 11 ARVC families for
mutations in TMEM43 and five desmosomal genes previously implicated in the disease. Functional studies were
performed in COS-7 cells transfected with wildtype, mutant, and 1:2 wildtype:mutant TMEM43 to determine the
effect of the Ser358Leu mutation on the stability and cellular localization of TMEM43 and other nuclear envelope
and desmosomal proteins, assessed by solubility assays and immunofluorescence imaging. mRNA expression was
assessed of genes potentially affected by dysfunction of the nuclear lamina.
Results: Three novel mutations in previously documented desmosomal genes, but no mutations in TMEM43, were
identified. COS-7 cells transfected with mutant TMEM43 exhibited no change in desmosomal stability. Stability and
nuclear membrane localization of mutant TMEM43 and of lamin B and emerin were normal. Mutant TMEM43 did
not alter the expression of genes located on chromosome 13, previously implicated in nuclear envelope protein
mutations leading to skeletal muscular dystrophies.
Conclusions: Mutant TMEM43 exhibits normal cellular localization and does not disrupt integrity and localization of
other nuclear envelope and desmosomal proteins. The pathogenetic role of TMEM43 mutations in ARVC remains
uncertain.
Background
Arrhythmogenic right ventricular dysplasia/cardiomyo-
pathy (ARVC) is an inherited disorder characterized by
replacement of cardiomyocytes by adipose and fibrous
tissue, primarily in the right ventricle (RV). This disrup-
tion can result in RV dysfunction, arrhythmias and sud-
den cardiac death. In the United States, 17% of sudden
death victims between the ages of 20 and 40 years had
ARVC. A large number of cases are unrecognized
because clinical tests are relatively insensitive to in vivo
detection of functional and structural changes in the RV
[1,2]. In approximately 40% of patients, mutations have
been identified in genes encoding constituent proteins
of cardiac desmosomes, namely, desmocollin-2 (DSC2),
desmoglein-2 (DSG2), desmoplakin (DSP), junctional
plakoglobin (JUP), and plakophilin-2 (PKP2)[3]. Muta-
tions can lead to instability of other desmosomal pro-
teins, resulting in their translocation from the cell
membrane to the cytoplasm [4,5].
We first mapped by genetic linkage analysis a large
family with ARVC to a 9.3 cM region on chromosome
3p23, known as locus ARVC5 [6]. Recently, Merner and
colleagues identified a c.1073 C > T mutation, leading
to a p.Ser358Leu substitution, in a highly conserved
region of transmembrane protein 43 (TMEM43) at this
locus in the same family [7]. TMEM43, also known as
LUMA, is a highly conserved inner nuclear membrane
(INM) protein. It has been suggested that TMEM43 can
cause pathological changes in the INM by affecting
other protein complexes in it [8]. Furthermore,
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immunostaining of cardiac tissue from subjects with
TMEM43 mutations indicated reduced expression of
TMEM43 and plakoglobin, with TMEM43 showing
localization at the sarcolemma [9]. However, little is
known about function of TMEM43 and the mechanism
by which mutations cause ARVC.
The overall goal of this study was to investigate the
mechanisms by which mutations in TMEM43 may lead
to ARVC. Given the novelty of the TMEM43 mutation
in the context of previously reported mutations that
were primarily in genes encoding desmosomal proteins,
we first sought to determine the prevalence of mutations
in TMEM43 relative to five desmosomal genes, namely,
DSC2, DSG2, DSP, JUP, PKP2, in 11 ARVC probands.
We found three novel mutations in different desmoso-
mal genes, however, TMEM43 mutations were absent in
these probands. Next, since common mechanisms often
underlie each cardiomyopathy even in the setting of
genetic heterogeneity, we conducted in vitro studies to
determine whether the functional abnormalities caused
by the rare TMEM43 S358L parallel those found in the
setting of desmosomal mutations. COS-7 cells were
transfected with either wildtype or mutant TMEM43, or
co-transfected with both. Our studies showed that
mutant TMEM43 protein did not disrupt interactions
among desmosomal and nuclear envelope proteins, and
did not lead to altered cellular localization of itself or of
desmosomal and nuclear envelope proteins. Further-
more, mutant TMEM43 did not alter the expression of
genes as observed in the cardiomyopathy caused by
mutations in the nuclear membrane-associated protein,
lamin A/C. Therefore, the role of the TMEM43 Ser358-
Leu mutation in ARVC remains uncertain.
Methods
Subjects
A total of 11 families with ARVC were recruited by the
University of Pittsburgh Cardiovascular Genetics Center
and the Harvard Medical School Department of Genetics,
in accordance with protocols approved by their respective
Institutional Review Boards. Informed consent was
obtained from all subjects. Clinical diagnosis of ARVC was
based on the recently modified criteria originally proposed
by the International Task Force of the European Society of
Cardiology and the International Society and Federation of
Cardiology [10]. Demographic and clinical data on pro-
bands and affected family members in whom a mutation
was identified are shown in Table 1.
Genetic mutation screening
TMEM43, DSC2, DSG2, DSP, JUP and PKP2 were
screened for mutations in all probands, followed by con-
firmation of any potential mutation in other available
family members. Primers were designed using the
Primer3 utility http://frodo.wi.mit.edu/. Each identified
mutation was screened in 150 unrelated and unaffected
control individuals to confirm its absence in normal
population. Point mutations were detected by PCR
amplification of exons, followed by direct sequencing
(ABI). Identified mutations were analyzed for pathogeni-
city by using (1) protein prediction algorithms PolyPhen
http://genetics.bwh.harvard.edu/pph/, SIFT http://sift.
jcvi.org/, MUpro http://www.ics.uci.edu/~baldig/muta-
tion.html and PMut http://mmb2.pcb.ub.es:8080/PMut/,
(2) evolutionary conservation among species using Clus-
talW analysis, and (3) localization within a functionally
important domain.
Construction of wildtype and mutant TMEM43 expression
vectors
Wildtype TMEM43
RNA was extracted from normal human heart tissue as
described elsewhere [11]. cDNA for TMEM43 was
synthesized using SuperScript reverse transcriptase
(Invitrogen). The sequence was verified by direct
sequencing. The resulting fragment was cloned into the
pcDNA3.1/NT-GFP-topo eukaryotic expression vector
(Invitrogen), which tags the expressed protein with GFP.
Cloning and transformation into chemically competent
E. coli cells was performed according to the manufac-
turer’s instructions. Plasmid DNA was isolated using the
QIAprep Spin Miniprep Kit (Qiagen) and quantified on
a UV spectrophotometer. The sequence was verified by
direct sequencing.
Ser358Leu mutant TMEM43
The QuickChange XL Site-Directed Mutagenesis Kit
(Stratagene) was used to introduce the Ser358Leu muta-
tion into the wildtype TMEM43 expression vector.
Mutagenic primers were designed according to the man-
ufacturer’s instructions. Plasmid DNA was isolated as
described above and presence of the Ser358Leu muta-
tion was verified by direct sequencing.
Cell culture and transfection
COS-7 cells were cultured in DMEM containing 10%
fetal bovine serum (FBS), streptomycin, and penicillin G
at concentrations of 100 μg/ml each, and transfected
using Lipofectamine 2000 (Invitrogen). Briefly, cells were
grown overnight in supplemented DMEM medium and
transfected in serum free medium with wildtype plasmid,
mutant plasmid, or wildtype and mutant plasmid (at
ratios of 1:1 and 1:2) for 6-8 hours. The medium in the
plates was then replaced by supplemented DMEM. Cells
were harvested five days following transfection.
Assessment of protein stability by solubility assays
Previous studies have suggested that disruption of cell-
cell adhesion because of desmosomal dysfunction is a
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major mechanism of ARVC. Structural instability of des-
mosomes leads to localization of constituent proteins in
the cytoplasmic instead of the cell membrane fraction
following centrifugation in the presence of nondenatur-
ing detergents such as Triton X-100 [5,12]. We assessed
the effect of mutant Ser358Leu TMEM43 on solubility
patterns of four desmosomal proteins (desmocollin-2,
desmoglein-2, desmoplakin, and junctional plakoglobin)
and the cellular distribution of three nuclear envelope
proteins (TMEM43, lamin B and emerin).
Solubility of desmosomal proteins
To evaluate the pathogenetic effect of mutant TMEM43
on desmosomal proteins, COS 7 cells were transfected
with either wildtype, mutant TMEM43, or both plasmids
at wildtype:mutant ratios of 1:1 and 1:2 for 5 days. Five
days following transfection, cells were washed in PBS
and lysed in Triton X lysis buffer (20 mM HEPES, pH
7.4, 150 mM NaCl, 0.5 mM CaCl2, and 1% Triton X-
100) [4], followed by centrifugation at 20,000 ×g for 15
min. The supernatant, comprised of the soluble fraction,
and the pellet (insoluble fraction) was resuspended in
RIPA buffer (Thermo Scientific). Protease inhibitor
tablets (Roche) were added to each of the protein frac-
tions and 40 μg of soluble and insoluble protein frac-
tions were loaded onto a 10% protein gel (Pierce).
Immunoblotting was performed as described elsewhere
[11]. The following primary antibodies and titers were
used following the manufacturer’s instructions: desmo-
collin-2/3 (Zymed Laboratories, #32-600, 1:125), desmo-
glein-2 (Abcam, #ab14415, 1:1000), desmoplakin (United
States Biological, #D3221-89, 1:100), and junctional pla-
koglobin (Zymed Laboratories, #13-8500, 1:125).
Solubility of TMEM43 and other nuclear envelope proteins
Unlike desmosomal and other nuclear envelope proteins,
TMEM43 readily solubilizes in Triton X-100. This effect
is obviated if the solubility assay is performed on
nuclear envelope extract rather than whole cell lysate
[8]. Hence, nuclear envelope membranes were extracted
from transfected COS- 7 cells, followed by solubility
assays. To extract the nuclear envelope, the cytoplasmic
fraction and nuclei of transfected cells were separated
using ProteoJET cytoplasmic and nuclear protein extrac-
tion kit (Fermentas). Nuclei were washed with 20 mM
HEPES buffer (pH 7.4) and nuclear envelope
Table 1 Clinical characteristics of ARVC subjects with mutations in desmosomal genes
ARVC diagnostic
criteria
Criteria
fulfilled
Subject
Family I.1 Family II.1 Family II.2 Family III.1 Family III.2 Family IV.1
Sex M M M F M M
Age at diagnosis
(years)
41 20 17 35 18 16
Global and regional
dysfunction and
structural alterations
Major 1 1 1 1 1
Minor 1
Tissue characterization Major 1 NA
Minor
Repolarization
abnormalities
Major NA
Minor
Depolarization/
conduction
abnormalities
Major NA
Minor
Arrhythmias Major 1 1 1 NA 1
Minor
Family history Major 1 1 NA NA
Minor
Mutation DSG2, c. 208A > G†
(Ile70Val), PKP2a, c.397
C > T (Gln133*)
DSC2, C.1234-
35insA†,(p.
Thr412Asnfs*2)
DSC2, C.1234-
35insA†, (p.
Thr412Asnfs*2)
PKP2, c.2540
delT†, (p.
Leu847Argfs*83)
PKP2, c.2540
delT†, (p.
Leu847Argfs*83)
PKP2, C.2197-
2202delinsG, (p.
His733Alafs*8)
Predicted functional
effect
DSG2, Ile70Val, Benign
Mutation screening in
150 normal healthy
controls
Absent Absent Absent Absent Absent ND (reported
earlier)
M, male; F, female; NA, not available; ND, Not determined; †, novel mutations reported in this study; numbering, number of major or minor criteria filled
Rajkumar et al. BMC Medical Genetics 2012, 13:21
http://www.biomedcentral.com/1471-2350/13/21
Page 3 of 9
membranes were prepared by treatment with heparin
and DNase I [13]. Briefly, heparin and DNase I were
added to the nuclei suspended in 20 mM HEPES at a
final concentration of 0.6 mg/108 nuclei and 0.5 mg/108
nuclei, respectively. The nuclei were stirred for 1 hour
at 4°C, followed by centrifugation at 12,000 ×g for 20
minutes (4°C). The pellet was resuspended in buffer (20
mM HEPES, pH 7.4, 1 mM MgCl2, 0.32 M sucrose, 42.8
mM b-mercaptoethanol), and centrifuged again as
described above. The pelleted nuclear envelope mem-
branes were lysed with Triton X lysis buffer, followed by
separation of the soluble and insoluble fraction, as
described earlier. Protease inhibitor tablets (Roche) were
added to both fractions. Approximately, 10 μg of soluble
and insoluble nuclear envelope protein was loaded on a
protein gel and immunoblotting was performed. Differ-
ential solubility patterns were assessed for TMEM43
(GFP antibody, Invitrogen, #A11122, 1:1000), lamin B
(Santa Cruz, #sc-6217, 1:1000) and emerin (Santa Cruz,
#sc-81552, 1:1000) by immunoblotting at the indicated
titers.
Immunofluorescence microscopy
COS-7 cells were grown and transfected in 8-well cham-
ber plates as described above. Cells were fixed using 2%
formaldehyde in phosphate buffer saline (PBS), permea-
bilized with 0.5% Triton-X-100 in PBS, and washed sev-
eral times with 0.5% bovine serum albumin (BSA) in
PBS. Primary antibodies against lamin B (Santa Cruz,
#sc-6217, 1:50) and emerin (Santa Cruz, #sc-81552,
1:50) were diluted in 0.5% BSA in PBS. Fixed cells were
incubated at 4°C overnight with the antibody at the
indicated titer, followed by incubation at room tempera-
ture for one hour with appropriate cyanine-3 labeled
secondary antibody. Nuclei were stained with Hoechst
stain (Invitrogen). Cells were visualized using Nikon
Eclipse TS 100 fluorescent microscope.
Real-time quantitative PCR (QPCR)
Mewborn and colleagues have previously shown that
chromosome 13 exhibits a high percentage of misex-
pressed genes in lamin A mutant hearts. Among these
genes, abnormal expression of KCTD12, LMO7,
MBNL2, and RAP2A were shown to be associated with
striated muscle dysfunction [14]. Lamin A/C also associ-
ates with TMEM43 [8]. Therefore, we quantified the
expression of these genes as described [11] in COS-7
cells transfected with either the wildtype or mutant
plasmid.
RNA was extracted from cells using Trizol (Invitro-
gen) and RNA quantity was determined on an Agilent
Nanodrop. One μg of total RNA was used to synthesize
cDNA using the SuperScript III First-Strand System
(Invitrogen). QPCR was performed using Express SYBR
GreenER kit with premixed ROX (Invitrogen) on gene
specific primers previously published by Mewborn and
colleagues [14]. Experiments were performed using two
biological replicates and three technical replicates. Sam-
ples were run on an ABI Prism 7000 Sequence Detec-
tion System. Threshold cycle values were normalized to
gylceraldehyde-3-phosphate dehydrogenase. ΔΔCt values
were estimated for each gene and unpaired Student’s t-
tests were performed to compare data obtained from
wildtype and mutant plasmid transfected cells. A value
of P < 0.05 was considered significant. Data are
expressed as mean ± standard deviation.
Results
Clinical evaluation and mutation screening
Novel variants were identified in three desmosomal
genes, DSG2, DSC2 and PKP2, that were absent in 150
control individuals. We also report two known muta-
tions in PKP2 (Table 1 and Figure 1).
Family I. The proband (I.1) was a compound heterozy-
gote with a novel DSG2 exon 3 mutation, c. 208A > G
(p.Ile70Val), and a previously reported PKP2 truncation
mutation, c.397 C > T (p.Gln133*). The Gln133* muta-
tion has been observed in patients that do not fully
satisfy ARVC diagnostic criteria [15]. The proband ful-
filled 2 major diagnostic criteria (Table 1) [10].
Although the DSG2 Ile70Val mutation was not pre-
dicted to be pathological, the Ile residue at this position
was highly conserved among species (Figure 1A). Each
of two available clinically unaffected family members
possessed either the DSG2 Ile70Val or the PKP2
Gln133* mutation.
Family II. The proband (II.1) had an insertion at
c.1234_1235insA in exon 9 of DSC2 resulting in a fra-
meshift followed by premature truncation of the protein
(p.Thr412Asnfs*2). This region is conserved among spe-
cies and the predicted protein would lack part of the
extracellular, transmembrane domain and cytoplasmic
components (Figure 1B). One affected sibling (II.2)
shared the same mutation as the proband (Table 1). The
clinical manifestation of the disease at a young age in
both the proband and the sibling is consistent with the
pathogenicity of the DSC2 Thr412Asnfs*2 mutation.
Family III. The proband (III.1) had a deletion at
c.2540delT in exon 13 of PKP2, resulting in a loss of a
stop codon and a mutant protein that was 48 amino
acids longer than the wildtype protein (p.
Leu847Argfs*83). This region is conserved among spe-
cies (Figure 1C). One other family member shared the
same deletion as the proband (III.2). The proband only
partially satisfied ARVC diagnostic criteria, probably
because the mutant protein functions similarly to the
wildtype PKP2 protein. There was insufficient clinical
information to make a diagnosis in family member III.2.
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S      P         EC1            EC2              EC3          EC4           EA   TM   IA   ICS     LD     RUD        TD
Homo sapiens R E G E D L S K K N P I A K I H S D L A E E R G L K I T
Pan troglodytes R E G E D L S K K N P I A K I H S D L A E E R G L K I T
Canis lupus 
familaris R E G E D L S K R N P I A K I H S D V A E E R G L K I T
Bos taurus R E G E D L S R K N P I A K I H S D L A E E K K L K I T
Mus musculus R E G E D L S R K N P I A K I H S D L A E E K G I K I T
Rattus 
norvegicus R E G E D L S K K N P I A K I H S D L A E E R G I K I T
Gallus gallus R E E E D N S Y R N P I A R I H S D F - E D T G I V V T
Danio rerio R E N V N Y M Y L D Y I A K I R S D E E - - T R T S I R
Consensus * * * * * * *
S        P         EC1           EC2             EC3          EC4      EA   TM       IA            ICS
                                             2        3      4       5       6      7                         8       9     10   11                          12             13      14            15  16   17      
3
p.Thr412Asnfs*2 
mo sapiens N F K I V T D A K T N E G V L C V V K P L N Y E E K Q
n troglodytes N F K I V T D A K T N E G V L C V V K P L N Y E E K Q
nis lupus
milaris N F K I V T D P K T N E G I L C V V K P L N Y E E R K
s taurus N F K I V T D S Q T N E G V L C V V K P L N Y E E K Q
s musculus N F K I V T D P K T N E G I L C V I K P L D Y E E R Q
ttus norvegicus N F K I K T D P Q T N E G I L C V I M P L D Y E E R Q
llus gallus T F E I T T D R N T N E G I L C V V K G L D Y E N A K
nsensus * * * * * * * * * * * * * *
1                                  2        3                          4                      5         6        7                 8        9        10    11        12         13                14    
3’U’UTR
p.Leu847Argfs*83
o sapiens S V L L Y S L W A H T E L H H A Y K K A Q F K
  lupus
aris S V L L Y S L W T H T E L H N A Y K K A Q F K
aurus S V L L Y S L W T H T E L H N A Y K K A Q F K
musculus S V L L Y S L W A H T E L H H A Y K K A Q F K
Figure 1 Significance of novel desmosomal mutations assessed by localization within functionally important domains and their
evolutionary conservation. (A) DSG2, p.Ile70Val (c.208A > G); (B) DSC2, p.Thr412Asnfs*2 (c.1234_1235insA); (C) PKP2, p.L847Rfs*83 (c.2540delT).
The numbered white box signifies an exon; the arrow signifies the site of mutation; the grey background indicates identity across species; the
box surrounding an amino acid indicates the mutated residue. S, signal domain; P, preprotein domain; EC, extracellular domain; EA, extracellular
anchor; TM, transmembrane domain; IA, intracellular anchor domain; ICS, intracellular cadherin-typical segment domain; LD, linker domain; RUD,
repeat unit domain; TD, terminal domain.
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Family IV. The proband (IV.1) fulfilled the ARVC
diagnostic criteria and presented with a previously
reported deletion and insertion in exon 11 of PKP2 at
c.2197-2202delinsG that resulted in a premature trunca-
tion of the protein (p.His733Alafs*8) (Table 1) [16].
No mutations in TMEM43 were identified in the 11
probands, suggesting that mutations in this gene are a
relatively rare cause of ARVC.
Functional characterization of mutant TMEM43
Desmosomal and nuclear envelope protein stability
Previous studies have suggested that disruption of cell-
cell adhesion because of desmosomal dysfunction is a
major mechanism of ARVC. Structural instability of des-
mosomes leads to localization of constituent proteins in
the cytoplasmic instead of the cell membrane fraction
following centrifugation in the presence of nondenatur-
ing detergents [5,12]. We assessed the effect of mutant
Ser358Leu TMEM43 on solubility patterns of four des-
mosomal proteins (desmocollin-2, desmoglein-2, desmo-
plakin, and junctional plakoglobin) and the cellular
distribution of three nuclear envelope proteins
(TMEM43, lamin B and emerin).
Solubility assays indicated similar localization of des-
mocollin-2, desmoglein-2, desmoplakin, and junctional
plakoglobin in the cell membrane bound insoluble frac-
tion, irrespective of the transfection dosage for both wild-
type and mutant TMEM43 (Figure 2A, data not shown
for 1:1 dosage). Mutant TMEM43 and lamin B were pre-
sent in the insoluble nuclear membrane bound fraction
(Figure 2B). Although emerin was present in both soluble
and insoluble fractions, there was no evident change in
the ratio between the two fractions. Immunofluorescence
microscopy also showed that TMEM43, lamin B, and
emerin were localized to the nuclear membrane in both
wildtype and mutant TMEM43 transfected cells (Figure
3). Thus, these data suggest that mutant TMEM43 does
not change its own localization or that of its binding
partners lamin B and emerin.
Gene expression changes
We examined the effect of mutant TMEM43 on mRNA
expression of four genes, LMO7, KCTD12, MBNL2 and
RAP2A, located on chromosome 13, that have been
shown to have abnormal expression in the setting of
laminopathies with striated muscle dysfunction [14].
QPCR preformed on these four genes showed no signifi-
cant change in their mRNA expression in cells trans-
fected with wildtype and mutant TMEM43, respectively
(Table 2). Thus, while TMEM43 interacts with lamin A,
we conclude that mutant TMEM43 protein, unlike
mutant lamin A, does not alter expression of at least
four representative genes on chromosome 13.
Discussion
The mechanisms by which mutant desmosomal proteins
cause ARVC have been partially elucidated. Previous
studies have shown that overexpression in cell lines of
mutant desmoplakin and desmocollin-2 associated with
ARVC results in cytoplasmic distribution of these pro-
teins instead of normal membrane localization [5,12]
and knockdown of DSP leads to nuclear localization of
plakoglobin [17]. In Pkp-/- null mice, plakophilin-2 and
plakoglobin were found to be essential for adherence of
desmoplakin to partner desmosomal proteins [4]. More
recently, the Ser358Leu mutation in TMEM43 has been
suggested [7] as a putative cause for ARVC in a large
kindred that we mapped to chromosome 3p23 [6].
Furthermore, decreased expression of plakoglobin has
been shown in tissues of patients with ARVC including
those with TMEM43 mutations [9,18]. To uncover
potential mechanisms by which TMEM43 mutations
may lead to ARVC, we first sought to determine its fre-
quency in the ARVC population by screening for muta-
tions in this gene along with five other desmosomal
genes; and we then examined the specific effects of
Ser358Leu mutant TMEM43 on stability of desmosomal
and nuclear envelope proteins and on gene expression
in the COS-7 heterologous cells system.
Our patient cohort lacked TMEM43 mutations, sug-
gesting that mutations in this gene are a relatively rare
cause of ARVC and consistent with a previously
reported screen [8]. However, we have identified three
novel mutations in three probands. The presence of two
mutations, i.e., p.Ile70Val in DSG2 and p.Gln133* in
PKP2 in the Family I proband, contrasted with unaf-
fected family members who had only one mutation
each, suggests that co-segregation of these two muta-
tions in the proband may have led to the development
of ARVC. Earlier studies have also suggested that
digenic and compound heterozygous mutations are fre-
quent in desmosomal genes and may be responsible for
severe ARVC [19-21]. The DSC2 (p.Thr412Asnfs*2) fra-
meshift mutation is likely pathogenic since it results in a
truncated protein and both individuals in Family II with
this mutation fulfilled ARVC diagnostic criteria.
As discussed earlier, ARVC is primarily a disease of
the desmosomes. Based on this observation, we
hypothesized that mutant TMEM43 protein would dis-
rupt structure and function of desmocollin-2, desmo-
glein-2, desmoplakin, and junctional plakoglobin,
leading to ARVC. However, we found no evidence of
disruption or mislocalization of mutant TMEM43 or of
desmosomal proteins in transfected COS-7 cells. Thus,
our data suggest that mutant TMEM43 does not directly
affect desmosomal protein localization on even increas-
ing the dosage of mutant protein.
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TMEM43 is an INM protein that has a large hydro-
philic domain located in the endoplasmic reticulum
(ER) lumen. It helps to maintain the nuclear envelope
structure by organizing protein complexes in the INM
and it is known to associate with other nuclear envelope
proteins such as lamins and emerin [8]. Lamins have
been extensively studied primarily because mutations in
lamin A/C lead to dilated cardiomyopathy [22] and
lamin B maintains nuclear shape and mechanical integ-
rity [23]. Since mutations in emerin cause Emery-Drei-
fuss muscular dystrophy and TMEM43 can affect
emerin distribution, it has been suggested that TMEM43
mutations could result in muscular dystrophy [8]. We
therefore sought to determine whether mutant
TMEM43 affects the localization of emerin and lamin B,
which in turn might lead to ARVC. However, our
solubility and immunofluorescence experiments indi-
cated no such abnormalities.
As mentioned above, mutations in lamin A can lead to
dilated cardiomyopathy. Lamin A/C, encoded by LMNA,
is also a member of the LINC complex (linker of
nucleoskeleton and cytoskeleton) that links the nucleus
to the cytoplasm and also associates with TMEM43.
Mewborn and colleagues showed that lamin A mutants
exhibited misexpression of genes located on chromo-
some 13, which may potentially lead to laminopathies
[14]. We therefore examined the effect of mutant
TMEM43 protein on mRNA expression of four genes,
namely, LMO7, KCTD12, MBNL2 and RAP2A, all of
which are located on chromosome 13, are associated
with striated muscle dysfunction, and exhibit abnormal
expression in the presence of a LMNA mutation [14].
JUP
Lamin B
Coomassie 
Blue
DSG2
GFP-TMEM43
Coomassie 
Blue
DSC2/3
Coomassie 
Blue
DSP
Emerin
Coomassie 
Blue
A.
B.
Soluble Insoluble
MutWT
WT+
Mut MutWT
WT+
Mut
WT Mut
Cyt NE Cyt NE
Sol Insol Sol Insol
Soluble Insoluble
MutWT
WT+
Mut MutWT
WT+
Mut
WT Mut
Cyt NE Cyt NE
Sol Insol Sol Insol
Figure 2 Solubility assays. Solubility patterns for (A) desmosomal and (B) nuclear envelope proteins were assessed by immunoblots for soluble
and insoluble protein fractions extracted from COS-7 cells transfected with wildtype (WT) TMEM43, mutant (Mut) TMEM43, or a 1:2 ratio of
wildtype to mutant (WT + Mut) TMEM43. Sol, soluble fraction containing cytoplasmic (Cyt) proteins; Insol, insoluble fraction containing
membrane bound proteins. No differences in solubility patterns were found, suggesting that the presence of mutant TMEM43 did not alter the
stability of TMEM43 or of other desmosomal or nuclear envelope proteins.
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However, in the presence of mutant TMEM43, these
genes exhibited normal mRNA expression.
Conclusions
We identified three new mutations in desmosomal genes
in 11 probands screen; however, no TMEM43 mutations
were identified. The absence of a mutation in majority
of our ARVC patients, as in prior studies, suggests the
presence of other genetic contributors to this disease.
This study also confirms normal cellular localization
and stability of the analyzed desmosomal and nuclear
proteins in COS 7 cells transfected with mutant
TMEM43. Furthermore, mutant TMEM43 did not alter
the expression of genes that are suggested to be asso-
ciated with laminopathies. A limitation of this study is
that a heterologous cell system was used, which may
not completely reflect the effect of TMEM43 mutations
in cardiomyocytes. Additional studies in cardiomyocytes
may be required to uncover a clearer pathogenetic link
between the Ser358Leu mutation in TMEM43 and the
development of ARVC.
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